SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Telomir Pharmaceuticals, Inc. (TELO) News

Follow Telomir Pharmaceuticals, Inc. (TELO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TELO Asset equity Sector Markets 90 days 4 Last 0.3619 Updated Sep 29, 2026, 07:31 AM UTC Open live news feed Open TELO chart & news
L Telo Genomics Corp. (TELO) Reports Preliminary TELO—MRD Data vs clonoSEQ and EuroFlow Telo Genomics reported preliminary research where blood-based TELO enumeration detected circulating plasma cells in all evaluable clonoSEQ-positive cases and in clonoSEQ-negative or non-evaluable samples; prior EuroFlow NEWS | Sep 29, 2026, 07:31 AM UTC L Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or non NEWS | Sep 29, 2026, 07:31 AM UTC L Telomir Pharmaceuticals says preclinical study restored AMD model visual function The company said a peer-reviewed preclinical study found Telomir-Zn restored visual function and retinal structure in an AMD model. EQUITY | Sep 17, 2026, 12:34 PM UTC L TELO - Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) TELO - Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) NEWS | Sep 17, 2026, 12:30 PM UTC